Table 3.
Concern about side effects of nanoformulated antiretroviral therapy.
| Parameter | Not at all concerned; n (%) |
A little concerned; n (%) |
Somewhat concerned; n (%) |
Very concerned; n (%) |
Total (n) |
p-value |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| 18–39 | 11 (13) | 12 (14) | 18 (21) | 44 (52) | 370 | 0.89 |
| 40–54 | 34 (17) | 34 (17) | 42 (21) | 86 (44) | ||
| 55+ | 11 (12) | 14 (16) | 20 (22) | 44 (49) | ||
| Gender | ||||||
| Male | 46 (18) | 48 (19) | 58 (23) | 99 (39) | 367 | <0.01 |
| Female | 9 (8) | 12 (10) | 22 (19) | 73 (63) | ||
| Race | ||||||
| African–American | 29 (16) | 21 (11) | 26 (14) | 109 (59) | 342 | 0.01 |
| White | 22 (14) | 32 (20) | 48 (31) | 55 (35) | ||
| Drug use | ||||||
| Used in past 6 months | 16 (14) | 19 (17) | 24 (21) | 55 (48) | 321 | 0.81 |
| Not used in past 6 months | 31 (15) | 31 (15) | 51 (25) | 94 (45) | ||
| Adherence | ||||||
| Missed doses in last 4 days | 7 (8) | 16 (18) | 20 (22) | 46 (52) | 374 | 0.11 |
| No missed doses in last 4 days | 49 (17) | 44 (15) | 60 (21) | 131 (46) | ||
| Ever missed a dose | 33 (14) | 37 (14) | 55 (23) | 118 (49) | 365 | 0.37 |
| Never missed a dose | 21 (17) | 20 (16) | 25 (20) | 56 (46) | ||
Differences between the 399 overall number of participants and the values listed are due to missing data for individual questions. Exceptions to this are for gender and race where, for purposes of the analyses, gender was limited to those who reported only ‘male’ or ‘female’, and race was limited only to those who reported ‘African–American’ or ‘white’.